enGene’s (ENGN) “Market Outperform” Rating Reiterated at JMP Securities

enGene (NASDAQ:ENGN)‘s stock had its “market outperform” rating reiterated by investment analysts at JMP Securities in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $18.00 price objective on the stock. JMP Securities’ price objective indicates a potential upside of 184.81% from the company’s current price.

ENGN has been the subject of a number of other research reports. HC Wainwright started coverage on enGene in a research report on Monday. They issued a “buy” rating and a $25.00 target price on the stock. Morgan Stanley reiterated an “overweight” rating and issued a $40.00 price objective on shares of enGene in a research note on Wednesday, September 11th. Citizens Jmp upgraded shares of enGene to a “strong-buy” rating in a research report on Monday, November 18th. Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 price target on shares of enGene in a report on Tuesday, September 24th. Finally, Raymond James began coverage on enGene in a research note on Wednesday, November 27th. They set an “outperform” rating and a $23.00 price objective for the company. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $29.78.

enGene Trading Up 6.0 %

NASDAQ:ENGN opened at $6.32 on Monday. The company has a market capitalization of $279.45 million, a P/E ratio of -10.90 and a beta of -0.78. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. enGene has a 12 month low of $4.42 and a 12 month high of $18.40. The firm has a fifty day simple moving average of $8.10 and a 200-day simple moving average of $7.78.

enGene (NASDAQ:ENGN) last issued its quarterly earnings results on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. On average, equities research analysts anticipate that enGene will post -1.52 earnings per share for the current year.

Insider Activity

In related news, major shareholder Growth Opportunities F. Forbion purchased 11,844 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The shares were purchased at an average price of $6.55 per share, with a total value of $77,578.20. Following the purchase, the insider now owns 2,469,833 shares of the company’s stock, valued at $16,177,406.15. The trade was a 0.48 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ronald Harold Wilfred Cooper acquired 10,000 shares of enGene stock in a transaction on Friday, September 27th. The shares were bought at an average price of $5.70 per share, with a total value of $57,000.00. Following the completion of the transaction, the chief executive officer now directly owns 10,000 shares of the company’s stock, valued at $57,000. This trade represents a ? increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 420,965 shares of company stock worth $2,651,103 in the last ninety days. Company insiders own 13.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wolverine Asset Management LLC purchased a new stake in enGene during the 3rd quarter worth approximately $37,000. Franklin Resources Inc. boosted its stake in shares of enGene by 48.7% in the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after acquiring an additional 389,918 shares during the last quarter. Logos Global Management LP increased its position in shares of enGene by 50.0% during the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after purchasing an additional 400,000 shares in the last quarter. SR One Capital Management LP acquired a new position in enGene in the 2nd quarter valued at $4,715,000. Finally, Point72 Asset Management L.P. raised its stake in enGene by 1,410.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after purchasing an additional 619,100 shares during the last quarter. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.